SK286513B6 - Použitie 4-Fluór-N-indan-2-ylbenzamidu na výrobu liečiva - Google Patents
Použitie 4-Fluór-N-indan-2-ylbenzamidu na výrobu liečiva Download PDFInfo
- Publication number
- SK286513B6 SK286513B6 SK1011-2003A SK10112003A SK286513B6 SK 286513 B6 SK286513 B6 SK 286513B6 SK 10112003 A SK10112003 A SK 10112003A SK 286513 B6 SK286513 B6 SK 286513B6
- Authority
- SK
- Slovakia
- Prior art keywords
- hypertension
- medicament
- treatment
- compound
- formula
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
- C07C233/65—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Hospice & Palliative Care (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Reproductive Health (AREA)
- Ophthalmology & Optometry (AREA)
- Gynecology & Obstetrics (AREA)
- Vascular Medicine (AREA)
- Obesity (AREA)
- Gastroenterology & Hepatology (AREA)
- Emergency Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP01102852 | 2001-02-13 | ||
PCT/EP2002/001443 WO2002064146A1 (en) | 2001-02-13 | 2002-02-12 | 4-fluoro-n-indan-2-yl benzamide and its use as pharmaceutical |
Publications (2)
Publication Number | Publication Date |
---|---|
SK10112003A3 SK10112003A3 (sk) | 2004-01-08 |
SK286513B6 true SK286513B6 (sk) | 2008-12-05 |
Family
ID=8176423
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SK1011-2003A SK286513B6 (sk) | 2001-02-13 | 2002-02-12 | Použitie 4-Fluór-N-indan-2-ylbenzamidu na výrobu liečiva |
Country Status (34)
Country | Link |
---|---|
US (3) | US6617359B2 (et) |
EP (1) | EP1361882B1 (et) |
JP (1) | JP4317689B2 (et) |
KR (1) | KR101017531B1 (et) |
CN (1) | CN100553631C (et) |
AT (1) | ATE344669T1 (et) |
AU (1) | AU2002253009B2 (et) |
BG (1) | BG66065B1 (et) |
BR (1) | BR0207178A (et) |
CA (1) | CA2437966C (et) |
CY (1) | CY1106278T1 (et) |
CZ (1) | CZ20032154A3 (et) |
DE (1) | DE60215919T2 (et) |
DK (1) | DK1361882T3 (et) |
EE (1) | EE05302B1 (et) |
ES (1) | ES2274025T3 (et) |
HK (1) | HK1062140A1 (et) |
HR (1) | HRP20030646A2 (et) |
HU (1) | HUP0302845A3 (et) |
IL (2) | IL157208A0 (et) |
MX (1) | MXPA03006841A (et) |
MY (1) | MY135778A (et) |
NO (1) | NO333522B1 (et) |
NZ (1) | NZ527469A (et) |
PE (1) | PE20020884A1 (et) |
PL (1) | PL363452A1 (et) |
PT (1) | PT1361882E (et) |
RS (1) | RS51645B (et) |
RU (1) | RU2308946C2 (et) |
SI (1) | SI1361882T1 (et) |
SK (1) | SK286513B6 (et) |
TW (1) | TWI241190B (et) |
WO (1) | WO2002064146A1 (et) |
ZA (1) | ZA200305412B (et) |
Families Citing this family (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MY136316A (en) * | 2001-02-13 | 2008-09-30 | Sanofi Aventis Deutschland | Acylated 6,7,8,9-tetrahydro-5h-benzocycloheptenyl amines and their use as pharmaceutical. |
TWI241190B (en) * | 2001-02-13 | 2005-10-11 | Aventis Pharma Gmbh | 4-Fluoro-N-indan-2-yl benzamide and its use as pharmaceutical |
TWI243164B (en) * | 2001-02-13 | 2005-11-11 | Aventis Pharma Gmbh | Acylated indanyl amines and their use as pharmaceuticals |
US7338956B2 (en) | 2002-08-07 | 2008-03-04 | Sanofi-Aventis Deutschland Gmbh | Acylamino-substituted heteroaromatic compounds and their use as pharmaceuticals |
US7186735B2 (en) | 2002-08-07 | 2007-03-06 | Sanofi-Aventis Deutschland Gmbh | Acylated arylcycloalkylamines and their use as pharmaceuticals |
EP1388342A1 (en) * | 2002-08-07 | 2004-02-11 | Aventis Pharma Deutschland GmbH | Acylated, heteroaryl-condensed cycloalkenylamines and their use as pharmaceuticals |
US7105513B2 (en) * | 2002-08-07 | 2006-09-12 | Sanofi-Avertis Deutschland Gmbh | Acylated, heteroaryl-condensed cycloalkenylamines and their use as pharmaceuticals |
EP1388341A1 (en) * | 2002-08-07 | 2004-02-11 | Aventis Pharma Deutschland GmbH | Acylamino-substituted heteroaromatic compounds and their use as pharmaceuticals |
RS52079B (sr) | 2002-10-21 | 2012-06-30 | Janssen Pharmaceutica N.V. | Supstituisani tetralini i indani i njihova primena |
US7045551B2 (en) * | 2002-11-22 | 2006-05-16 | Bristol-Myers Squibb Company | 1-aryl-2-hydroxyethyl amides as potassium channel openers |
US7132536B2 (en) * | 2003-04-24 | 2006-11-07 | Sanofi-Aventis Deutschland Gmbh | Triaza- and tetraaza-anthracenedione derivatives, their preparation and their use as pharmaceuticals |
EP1644320B1 (en) * | 2003-07-03 | 2008-01-16 | Eli Lilly And Company | Indane derivates as muscarinic receptor agonists |
WO2005018620A2 (en) * | 2003-08-26 | 2005-03-03 | Cell Center Cologne Gmbh | Use of nitric oxide synthase (nos) cofactor for the treatment of sexual dysfunction |
EP1529525A1 (en) * | 2003-11-06 | 2005-05-11 | Aventis Pharma Deutschland GmbH | ENOS transcription enhancers for use in the cell therapy of ischemic heart diseases |
US8309608B2 (en) * | 2003-11-06 | 2012-11-13 | Sanofi-Aventis Deutschland Gmbh | Use of eNOS transcription enhancers in the cell therapy of ischemic heart diseases |
SI3138566T1 (sl) * | 2003-11-17 | 2022-04-29 | Biomarin Pharmaceutical Inc. | Postopki in sestavki za zdravljenje presnovnih motenj |
AR048931A1 (es) | 2004-04-21 | 2006-06-14 | Janssen Pharmaceutica Nv | Proceso para la preparacion de derivados de tetralina sustituida e indano sustituido y preparacion de intermediarios de sintesis |
EP2436379A1 (en) * | 2004-11-17 | 2012-04-04 | BioMarin Pharmaceutical Inc. | Stable tablet formulation |
EP1814553A4 (en) * | 2004-11-19 | 2009-10-28 | Childrens Hosp Medical Center | GTPASE INHIBITORS AND THEIR USE IN CONTROLLING PLATELET HYPERACTIVITY |
US20060185492A1 (en) | 2005-02-18 | 2006-08-24 | Francois Chianese | Shoulder bushing for saw blades |
EP1741708A1 (en) | 2005-06-28 | 2007-01-10 | Sanofi-Aventis Deutschland GmbH | Heteroaryl-substituted amides comprising an unsaturated or cyclic linker group, and their use as pharmaceuticals |
EP1741709A1 (en) | 2005-06-28 | 2007-01-10 | Sanofi-Aventis Deutschland GmbH | Heteroaryl-substituted amides comprising a saturated linker group, and their use as pharmaceuticals |
US7795101B2 (en) * | 2006-04-03 | 2010-09-14 | United Microelectronics Corp. | Method of forming a MOS transistor |
EP1905764A1 (en) | 2006-09-30 | 2008-04-02 | Sanofi-Aventis | Substituted 2-Phenyl-benzimidazoles and their use as pharmaceuticals |
EP1923062A1 (en) | 2006-11-16 | 2008-05-21 | sanofi-aventis | Imidazo[2,1-b]thiazoles and their use as pharmaceuticals |
KR101349187B1 (ko) * | 2006-12-05 | 2014-01-10 | (주)아모레퍼시픽 | 지방대사 이상질환의 치료 및 예방용 약학 조성물 |
EP1942104A1 (en) | 2006-12-20 | 2008-07-09 | sanofi-aventis | Heteroarylcyclopropanecarboxamides and their use as pharmaceuticals |
EP1939180A1 (en) | 2006-12-20 | 2008-07-02 | sanofi-aventis | Heteroarylacrylamides and their use as pharmaceuticals for the stimulation of the expression of endothelial NO synthase |
EP1939181A1 (en) | 2006-12-27 | 2008-07-02 | sanofi-aventis | Heteroaryl-substituted carboxamides and use thereof for the stimulation of the expression of NO synthase |
EP1964840A1 (en) | 2007-02-28 | 2008-09-03 | sanofi-aventis | Imidazo[1,2-a]pyridines and their use as pharmaceuticals |
EP1964841A1 (en) | 2007-02-28 | 2008-09-03 | sanofi-aventis | Imidazo[1,2-a]azine and their use as pharmaceuticals |
US20160169868A9 (en) * | 2007-05-24 | 2016-06-16 | Calcimedica, Inc. | Calcium channel proteins and uses thereof |
MX2010003923A (es) * | 2007-10-09 | 2010-05-05 | Novartis Ag | Formulacion farmaceutica de valsartan. |
WO2011115804A1 (en) | 2010-03-17 | 2011-09-22 | Ironwood Pharmaceuticals, Inc. | Sgc stimulators |
WO2012003405A1 (en) | 2010-06-30 | 2012-01-05 | Ironwood Pharmaceuticals, Inc. | Sgc stimulators |
MX341531B (es) | 2010-11-09 | 2016-08-22 | Ironwood Pharmaceuticals Inc | Derivados de triazol como estimuladores de la guanilato ciclasa soluble gcs. |
US9216178B2 (en) | 2011-11-02 | 2015-12-22 | Biomarin Pharmaceutical Inc. | Dry blend formulation of tetrahydrobiopterin |
CA2861804C (en) | 2011-12-27 | 2021-10-26 | Ironwood Pharmaceuticals, Inc. | 2-benzyl,3(pyrimidin-2-yl)substituted pyrazoles useful as sgc stimulators |
US9309235B2 (en) | 2012-09-18 | 2016-04-12 | Ironwood Pharmaceuticals, Inc. | SGC stimulators |
CA2885645A1 (en) | 2012-09-19 | 2014-03-27 | Ironwood Pharmaceuticals, Inc. | Sgc stimulators |
AU2014227862C1 (en) | 2013-03-15 | 2019-05-30 | Cyclerion Therapeutics, Inc. | sGC stimulators |
CN106304835A (zh) | 2013-12-11 | 2017-01-04 | 铁木医药有限公司 | sGC刺激剂 |
US20160324856A1 (en) | 2014-01-13 | 2016-11-10 | Ironwood Pharmaceuticals, Inc. | Use of sgc stimulators for the treatment of neuromuscular disorders |
US10028503B2 (en) | 2014-06-18 | 2018-07-24 | Children's Hospital Medical Center | Platelet storage methods and compositions for same |
WO2016044445A2 (en) | 2014-09-17 | 2016-03-24 | Ironwood Pharmaceuticals, Inc. | sGC STIMULATORS |
AU2015317824A1 (en) | 2014-09-17 | 2017-03-23 | Cyclerion Therapeutics, Inc. | Pyrazole derivatives as sGC stimulators |
MX2017003518A (es) | 2014-09-17 | 2017-07-28 | Ironwood Pharmaceuticals Inc | Estimuladores de guanilato ciclasa soluble (sgc). |
MA45588A (fr) | 2016-07-07 | 2019-05-15 | Ironwood Pharmaceuticals Inc | Formes solides d'un stimulateur de la gcs |
CA3029374A1 (en) | 2016-07-07 | 2018-01-11 | Ironwood Pharmaceuticals, Inc. | Phosphorus prodrugs of sgc stimulators |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6180597B1 (en) | 1998-03-19 | 2001-01-30 | Brigham And Women's Hospital, Inc. | Upregulation of Type III endothelial cell nitric oxide synthase by rho GTPase function inhibitors |
AU4990599A (en) | 1998-07-14 | 2000-02-07 | Brigham And Women's Hospital | Upregulation of type iii endothelial cell nitric oxide synthase by agents that disrupt actin cytoskeletal organization |
AUPP891299A0 (en) * | 1999-02-26 | 1999-03-25 | Fujisawa Pharmaceutical Co., Ltd. | New 6-membered cyclic compounds |
AU6497701A (en) * | 2000-05-30 | 2001-12-11 | Merck & Co Inc | Melanocortin receptor agonists |
TWI241190B (en) * | 2001-02-13 | 2005-10-11 | Aventis Pharma Gmbh | 4-Fluoro-N-indan-2-yl benzamide and its use as pharmaceutical |
MY136316A (en) * | 2001-02-13 | 2008-09-30 | Sanofi Aventis Deutschland | Acylated 6,7,8,9-tetrahydro-5h-benzocycloheptenyl amines and their use as pharmaceutical. |
TWI243164B (en) * | 2001-02-13 | 2005-11-11 | Aventis Pharma Gmbh | Acylated indanyl amines and their use as pharmaceuticals |
PE20020856A1 (es) * | 2001-02-13 | 2002-11-11 | Aventis Pharma Gmbh | 1,2,3,4-tetrahidronaftil aminas aciladas |
US7105513B2 (en) * | 2002-08-07 | 2006-09-12 | Sanofi-Avertis Deutschland Gmbh | Acylated, heteroaryl-condensed cycloalkenylamines and their use as pharmaceuticals |
US7186735B2 (en) * | 2002-08-07 | 2007-03-06 | Sanofi-Aventis Deutschland Gmbh | Acylated arylcycloalkylamines and their use as pharmaceuticals |
US7338956B2 (en) * | 2002-08-07 | 2008-03-04 | Sanofi-Aventis Deutschland Gmbh | Acylamino-substituted heteroaromatic compounds and their use as pharmaceuticals |
US8309608B2 (en) * | 2003-11-06 | 2012-11-13 | Sanofi-Aventis Deutschland Gmbh | Use of eNOS transcription enhancers in the cell therapy of ischemic heart diseases |
-
2002
- 2002-02-08 TW TW091102292A patent/TWI241190B/zh not_active IP Right Cessation
- 2002-02-11 MY MYPI20020481A patent/MY135778A/en unknown
- 2002-02-12 CZ CZ20032154A patent/CZ20032154A3/cs unknown
- 2002-02-12 EP EP02722066A patent/EP1361882B1/en not_active Expired - Lifetime
- 2002-02-12 SI SI200230443T patent/SI1361882T1/sl unknown
- 2002-02-12 CA CA2437966A patent/CA2437966C/en not_active Expired - Fee Related
- 2002-02-12 IL IL15720802A patent/IL157208A0/xx unknown
- 2002-02-12 HU HU0302845A patent/HUP0302845A3/hu unknown
- 2002-02-12 DE DE60215919T patent/DE60215919T2/de not_active Expired - Lifetime
- 2002-02-12 PT PT02722066T patent/PT1361882E/pt unknown
- 2002-02-12 CN CNB028048636A patent/CN100553631C/zh not_active Expired - Fee Related
- 2002-02-12 RU RU2003127750/15A patent/RU2308946C2/ru not_active IP Right Cessation
- 2002-02-12 MX MXPA03006841A patent/MXPA03006841A/es active IP Right Grant
- 2002-02-12 NZ NZ527469A patent/NZ527469A/xx not_active IP Right Cessation
- 2002-02-12 SK SK1011-2003A patent/SK286513B6/sk not_active IP Right Cessation
- 2002-02-12 AT AT02722066T patent/ATE344669T1/de active
- 2002-02-12 JP JP2002563939A patent/JP4317689B2/ja not_active Expired - Fee Related
- 2002-02-12 WO PCT/EP2002/001443 patent/WO2002064146A1/en active IP Right Grant
- 2002-02-12 BR BR0207178-9A patent/BR0207178A/pt not_active Application Discontinuation
- 2002-02-12 RS YU61703A patent/RS51645B/en unknown
- 2002-02-12 AU AU2002253009A patent/AU2002253009B2/en not_active Ceased
- 2002-02-12 EE EEP200300368A patent/EE05302B1/et not_active IP Right Cessation
- 2002-02-12 DK DK02722066T patent/DK1361882T3/da active
- 2002-02-12 ES ES02722066T patent/ES2274025T3/es not_active Expired - Lifetime
- 2002-02-12 KR KR1020037010490A patent/KR101017531B1/ko not_active IP Right Cessation
- 2002-02-12 PL PL02363452A patent/PL363452A1/xx not_active Application Discontinuation
- 2002-02-13 US US10/073,330 patent/US6617359B2/en not_active Expired - Lifetime
- 2002-02-13 PE PE2002000123A patent/PE20020884A1/es not_active Application Discontinuation
-
2003
- 2003-07-14 ZA ZA200305412A patent/ZA200305412B/xx unknown
- 2003-07-15 BG BG107994A patent/BG66065B1/bg unknown
- 2003-07-22 US US10/623,775 patent/US6812253B2/en not_active Expired - Lifetime
- 2003-08-03 IL IL157208A patent/IL157208A/en not_active IP Right Cessation
- 2003-08-11 NO NO20033546A patent/NO333522B1/no not_active IP Right Cessation
- 2003-08-12 HR HR20030646A patent/HRP20030646A2/hr not_active Application Discontinuation
-
2004
- 2004-06-11 HK HK04104235.3A patent/HK1062140A1/xx not_active IP Right Cessation
- 2004-08-18 US US10/920,395 patent/US7202278B2/en not_active Expired - Lifetime
-
2006
- 2006-12-06 CY CY20061101753T patent/CY1106278T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SK286513B6 (sk) | Použitie 4-Fluór-N-indan-2-ylbenzamidu na výrobu liečiva | |
AU2002253009A1 (en) | 4-fluoro-N-indan-2-yl benzamide and its use as pharmaceutical | |
JP4537653B2 (ja) | アシル化1,2,3,4−テトラヒドロナフチルアミンおよび医薬としてのその使用 | |
JP5618548B2 (ja) | イミダゾ[1,2−a]ピリジンおよびそれらの薬剤としての使用 | |
EP1534275B1 (en) | Acylamino-substituted heteroaromatic compounds and their use as pharmaceuticals | |
NO330011B1 (no) | Acylerte heteroarylkondenserte sykloalkenylaminer og deres anvendelse for fremstilling av farmasoytiske midler,samt farmasoytisk preparat inneholdende minst en slik forbindelse | |
JP2004518720A (ja) | アシル化6,7,8,9−テトラヒドロ−5h−ベンゾシクロヘプテニルアミンおよび医薬としてのその使用 | |
JP2010519321A (ja) | イミダゾ[1,2−a]アジンおよびそれらの薬剤としての使用 | |
PL210930B1 (pl) | Acylowane arylocykloalkiloaminy, ich zastosowanie jako środków farmaceutycznych, preparat farmaceutyczny oraz zastosowanie tych związków do wytwarzania środka leczniczego | |
US20070066577A1 (en) | Benzoxazole derivative or analogue thereof for inhibiting 5-lipoxygenase and pharmaceutical composition containing same | |
US8168665B2 (en) | Substituted 2-phenyl-benzimidazoles and their use as pharmaceuticals |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Patent lapsed due to non-payment of maintenance fees |
Effective date: 20130212 |